Apricus Biosciences (APRI) Tops Q2 EPS by 3c

Apricus Biosciences (NASDAQ: APRI) reported Q2 EPS of ($0.13), $0.03 better than the analyst estimate of ($0.16).

“In the second quarter of this year, we continued to execute on our strategy by creating a stable, financially healthier organization focused on resubmission of the Vitaros NDA,” stated Richard W. Pascoe, Chief Executive Officer. “We have improved our financial outlook through a combination of fundraising and expense reduction, resulting in a balance sheet that is expected to fund our current operating plan through the third quarter of 2018. Importantly, we have completed the final draft of the Vitaros NDA and we expect to re-submit the Vitaros NDA this quarter with an anticipated FDA approval decision in the first quarter of 2018. For the remainder of 2017, we will focus on working with the FDA regarding the Vitaros NDA, maintaining a productive dialogue with Allergan regarding the commercial potential for Vitaros in the United States, securing a development partner for RayVa, and continuing to diligently manage our corporate resources.”

For earnings history and earnings-related data on Apricus Biosciences (APRI) click here.

You May Also Be Interested In

• Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
• What Delta’s report tells investors in American and United
• Levi (LEVI) Tops Q2 EPS by 4c, Offers Guidance